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This article reviews the pharmacokinetics and
pharmacodynamics of angiotensin II (AII) receptor
antagonists (AIIRA), with particular focus on the
novel compound irbesartan. Irbesartan has the
highest oral bioavailability in its class (60% to
80%) and, unlike valsartan, its absorption is not
affected by food. Irbesartan displays linear, dose
related pharmacokinetics and, with the exception
of tasosartan’s active metabolite, has the longest
elimination half-life of the AIIRA (11 to 15 h).
Irbesartan exhibits the lowest amount of protein
binding, limiting its potential for drug interactions.
No drug interactions with irbesartan have been
identified. Unlike losartan, candesartan, and
tasosartan, irbesartan does not require
biotransformation for AII blockade. The
pharmacokinetics of irbesartan are not altered in
renally or hepatically impaired patients, probably
owing to excretion characteristic by both biliary
and renal routes, or by differences in gender or
age. Within its therapeutic dose range (150 to 300
mg), irbesartan shows sustained, dose related
blockade 24 h after dosing. Irbesartan lowers blood
pressure in a dose related manner up to 300 mg
daily. Some clear differences in pharmacokinetics
and pharmacodynamics exist among the AIIRA,
which may have clinical implications. Am J
Hypertens 1997;10:311S–317S © 1997 American
Journal of Hypertension, Ltd.
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Angiotensin II (AII) receptor antagonists(AIIRA) are a new class of antihyperten-sive agents that inhibit the renin-angioten-sin system by selectively blocking the AT1
subtype of AII receptors.1 These compounds were de-
veloped based on the assumption that AII plays a role
in the development of hypertension and cardiovascu-
lar disease. If this assumption is correct, it should be
possible to show some direct relationship between
these compounds and the doses administered, plasma
drug concentrations, and their effect on the AT1 recep-
tor. The pharmacokinetics and pharmacodynamics of
AIIRA are reviewed in this article, with particular
focus on the novel compound irbesartan (Figure 1). As
will be shown, despite sharing a common mechanism
of action, differences do exist among the AIIRA that
may result in different efficacy or tolerability profiles.
PHARMACOKINETIC PROFILE
OF IRBESARTAN
Irbesartan has an excellent pharmacokinetic profile
that is unique among AIIRA (Table 1). It has the
highest oral bioavailability in its class, is well absorbed
in the presence or absence of food, has a prolonged
elimination half-life (T1/2), has the highest plasma free
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fraction of the AIIRA, and does not rely on biotrans-
formation for its pharmacologic effect. In addition, the
pharmacokinetics of irbesartan are not altered in pa-
tients with renal or hepatic impairment or based on
differences in gender or age.
Absorption The oral absorption of irbesartan is
rapid and complete, with an average absolute bio-
availability of 60% to 80%.2 Its oral bioavailability is
higher than that of other AIIRA, including losartan
(33%)3 and valsartan (10% to 35%) (Table 1).4 Peak
plasma concentrations of irbesartan are attained
within 1.5 to 2 h after oral administration (Figure 2).5
Food does not affect the bioavailability of irbesartan,6,7
whereas food decreases the area under the concentra-
tion-time curve (AUC) of valsartan by 40% and re-
duces the maximum concentration (Cmax) by 50%.
4
The absorption of losartan is slightly delayed by food.3
The results of two double-blind, placebo controlled
studies involving 88 healthy subjects demonstrate that
irbesartan displays linear, dose-related pharmacoki-
netics (Figure 3) and, with the exception of tasosar-
tan’s active metabolite, has the longest T1/2 (11 to 15 h)
of the AIIRA (Table 1)5 (data on file, Bristol-Myers
Squibb/Sanofi). Steady state concentrations of irbesar-
tan are achieved within 3 days of once daily oral
dosing, and limited accumulation of irbesartan is ob-
served in plasma with repeated administration.5
Protein Binding Another distinguishing feature of
irbesartan is that it has the highest plasma free fraction
(10%) in its class (data on file, Bristol-Myers Squibb/
Sanofi), limiting the potential for interaction with
drugs highly bound to proteins. Losartan,3 EXP 3174,3
valsartan,4 and candesartan8 are more highly bound to
plasma proteins (Table 1).
Metabolism and Excretion Irbesartan does not re-
quire biotransformation for its pharmacologic activi-
ty.9 In contrast, much of the AII inhibiting effect of
losartan, candesartan, and tasosartan can be attributed
to their active metabolites—EXP 3174,10 CV-11974,8
and enoltasosartan,11 respectively. The results of in
vitro studies indicate that glucuronidation and oxida-
tion are the major routes of metabolism of irbesartan
and that the cytochrome P450 isoform 2C9 is the pri-
mary pathway for oxidation12 (data on file, Bristol-
Myers Squibb/Sanofi). Metabolism by the cytochrome
P450 isoform 3A4 is negligible.
Irbesartan metabolites have been identified in hu-
man plasma, urine, and feces. Following oral or intra-
venous administration of 14C-labeled irbesartan, more
than 80% of the circulating plasma radioactivity is
attributable to unchanged irbesartan. The primary cir-
FIGURE 1. Chemical structure of irbesartan.
TABLE 1. OVERVIEW OF THE PHARMACOKINETICS OF ANGIOTENSIN II BLOCKERS
Drug [Active Metabolite] Bioavailability Food Effect
Active
Metabolite
Half-life
(h)
% Protein
Binding Dosage (mg)
Losartan3 [EXP 3174] 33% Minimal Yes 2
[6–9]
98.7
[99.8]
50–100 daily or
50 twice daily
Valsartan4,28 25%
range: 10%–35%
2 40%–50% No 6 95.0 80–320 daily
Candesartan8,29,30 [CV-11974] N/A No Yes 3.5–4
[3–11]
99.5 N/A
Tasosartan11,31
[Enoltasosartan]
N/A No Yes 3–7
[34–43]
N/A N/A
Irbesartan2,5–7 (data on file,
Bristol-Myers
Squibb/Sanofi)
range: 60%–80% No No 11–15 90.0 150–300 daily
N/A, not available; 2, decrease by.
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culating metabolite is the irbesartan glucuronide
(;6%). Irbesartan and its metabolites are excreted by
both biliary and renal routes. About 20% of radioac-
tivity is recovered in the urine and the remainder in
the feces (data on file, Bristol-Myers Squibb/Sanofi).
Patients With Renal or Hepatic Impairment An
open label, parallel study compared the single dose
and steady state pharmacokinetics of irbesartan in 39
patients with varying degrees of renal function, as
assessed by 24 h creatinine clearance (CrCl).13 Patients
had either normal (24-h CrCl . 74 mL/min/1.73 m2),
mild-to-moderate (24 h CrCl 30 to 74 mL/min/1.73
m2), or severe (24 h CrCl , 30 mL/min/1.73 m2) renal
impairment, or required hemodialysis. Irbesartan was
administered at a once daily dosage of 100 mg for 8
days. Patients on hemodialysis received a higher dose
of irbesartan (300 mg) for 9 days to provide better
blood pressure control. There were no statistically sig-
nificant differences among the four groups in the dose
normalized AUC for irbesartan (Figure 4) and no in-
dication of drug accumulation. Irbesartan was not
cleared by hemodialysis, as the concentrations of irbe-
sartan in the venous and arterial blood of patients
during hemodialysis were similar.
Another open label, parallel study compared the
single dose and steady state pharmacokinetics of irbe-
sartan in 10 patients with hepatic cirrhosis and a
matched group of 10 subjects with normal hepatic
function.14 Irbesartan was administered at a once daily
dosage of 300 mg for 7 days. There were no statisti-
cally significant differences between the two groups in
AUC or Cmax of irbesartan (Figure 5) and no indication
of drug accumulation. The time of maximum concen-
tration (Tmax) and T1/2 of irbesartan also remained
constant.
Thus, the pharmacokinetics of irbesartan are not
altered in patients with renal or hepatic impairment
and, therefore, no adjustment of irbesartan dosage is
necessary in these patient populations. These findings
are likely due to irbesartan’s dual excretion character-
FIGURE 2. Mean plasma con-
centrations of irbesartan after a sin-
gle oral dose and at steady state after
once daily oral dosing for 7 days in
healthy subjects (n 5 8 or 9/group).
FIGURE 3. Mean area under the concentration–time curve
during a dosing interval (AUCTAU) at steady state after once daily
oral dosing with irbesartan for 7 days in healthy subjects (n 5 8
to 9/group); bars represent standard deviation.
FIGURE 4. Dose normalized mean area under the concentra-
tion–time curve (AUC) at steady state after once daily oral dosing
with irbesartan 100 mg for 8 days (or 300 mg for 9 days for the
hemodialysis group) in patients with varying degrees of renal
impairment (n 5 9 to 10/group); bars represent standard devia-
tion.
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istic. In contrast, plasma concentrations of losartan
and its active metabolite are reported to be 5 times and
1.7 times higher, respectively, in patients with mild-
to-moderate hepatic cirrhosis compared with normal
subjects.3 A lower starting dosage of losartan may
therefore be required in patients with a history of
hepatic impairment.3
Age or Gender Differences The single dose phar-
macokinetics of irbesartan were assessed in an open
label, parallel study involving 48 healthy subjects.15
Subjects were classified as young men (mean age, 30
years), young women (mean age, 31 years), elderly
men (mean age, 72 years), and elderly women (mean
age, 69 years). Irbesartan was administered as a 50 mg
dose after an overnight fast. No statistically significant
gender related effects were observed in AUC to infin-
ity (AUC0–`), Cmax, Tmax, or T1/2. The geometric mean
AUC0–` and Cmax of irbesartan were statistically sig-
nificantly increased in elderly subjects compared with
those of young subjects; however, the T1/2 of irbesar-
tan and the total cumulative amount of irbesartan
excreted unchanged in the urine were comparable in
these patient subgroups.
Because the previous study was conducted with a
50 mg oral dose, which is not within the therapeuti-
cally effective dose range of irbesartan (150 to 300 mg),
another open label, parallel study was performed to
assess the effect of age on the pharmacokinetics of a
higher dose of irbesartan.16 In this study, 12 healthy
young subjects (mean age, 29 years) and 12 healthy
elderly subjects (mean age, 69 years) received a single,
oral dose of irbesartan 150 mg after an overnight fast.
No statistically significant differences were observed
between the two groups in AUC0–`, Cmax, Tmax, or
T1/2; mean AUC0–` and Cmax were about 20% higher
in elderly subjects.
Based on the comparable efficacy and safety profile
of irbesartan in young and elderly patients with hy-
pertension (data on file, Bristol-Myers Squibb/Sanofi),
the magnitude of the observed pharmacokinetic dif-
ferences by age do not appear to be clinically signifi-
cant. Thus, no adjustment of irbesartan dosage is nec-
essary based on gender or age.
DRUG INTERACTIONS WITH IRBESARTAN
The pharmacokinetics of irbesartan are not affected by
coadministration of nifedipine or hydrochlorothiazide.
In addition, irbesartan has no effect on the pharmacody-
namics of warfarin (prothrombin time) or the pharma-
cokinetics of digoxin.
Nifedipine In an open label, crossover study,17 12
healthy subjects received irbesartan 300 mg once daily
for 4 days in one period and irbesartan 300 mg once
daily plus long acting nifedipine 30 mg once daily for
4 days in the other period. The order of treatment
periods was randomized and a minimum 7 day wash-
out phase separated the two periods. The pharmaco-
kinetics of irbesartan were not altered by concomitant
nifedipine administration. Furthermore, steady state
AUC during a dosing interval (AUCTAU) and Cmax
met the criteria for bioequivalence when irbesartan
was administered alone or with nifedipine.
Hydrochlorothiazide A randomized, double blind,
placebo controlled study in 36 patients with mild-to-
moderate hypertension (seated diastolic blood pres-
sure 95 to 110 mm Hg) compared the pharmacokinet-
ics of irbesartan when administered alone and in com-
bination with hydrochlorothiazide.18 The study
consisted of a placebo lead in period to establish the
stability of blood pressure, a 7 day, single blind treat-
ment period (irbesartan 150 mg once daily), and a 7
day, double blind treatment period (irbesartan 150 mg
once daily plus either placebo or hydrochlorothiazide
25 mg once daily). The pharmacokinetic profile of
irbesartan was not affected by the addition of hydro-
chlorothiazide.
Warfarin A double blind, placebo controlled study
in 16 healthy subjects assessed the effect of single and
multiple doses of irbesartan on the pharmacodynam-
ics of warfarin (data on file, Bristol-Myers Squibb/
Sanofi). On day 1, all subjects received warfarin 10 mg.
On days 2 to 14, subjects received individualized
doses of warfarin (2.5 to 10 mg once daily) sufficient to
achieve a prothrombin time ratio of 1.3 to 1.6. On days
15 to 22, irbesartan 300 mg once daily or placebo was
added to the subject’s individualized maintenance
dosage of warfarin. No differences were observed be-
tween the two groups in mean changes from baseline
in prothrombin time ratio. Thus, no adjustment of
FIGURE 5. Mean area under the concentration–time curve
(AUC) and maximum concentration (Cmax) at steady state after
once daily oral dosing with irbesartan 300 mg for 7 days in
subjects with and without hepatic impairment (n 5 10/group);
bars represent standard deviation.
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warfarin dosage is necessary when administered with
irbesartan.
Digoxin An open label study assessed the effect of
concomitant administration of irbesartan on the
steady state pharmacokinetics of digoxin (data on file,
Bristol-Myers Squibb/Sanofi). Ten healthy subjects re-
ceived digoxin 0.25 mg every 6 h on day 1, digoxin
0.25 mg once daily on days 2 to 7, and then digoxin
0.25 mg once daily plus irbesartan 150 mg once daily
on days 8 to 14. Irbesartan did not affect the pharma-
cokinetics of digoxin.
DOSE RELATED PHARMACODYNAMIC
EFFECTS OF IRBESARTAN
The effectiveness and persistence of AIIRA at inhibit-
ing the blood pressure response to AII in healthy
subjects is a good predictor of their efficacy in hyper-
tensive patients. Irbesartan has a dose related antihy-
pertensive effect up to the highest clinical dose of 300
mg daily. With losartan such a clear dose-response
relationship has not been demonstrated.
Preclinical Studies Irbesartan displays dose related
and insurmountable antagonism in vitro in rabbit
aorta9 and in vivo in pithed rats.19 Irbesartan blunts
the maximal contractile response of rabbit aorta to
high levels of AII. With increasing concentrations of
irbesartan, the contractile response curve is shifted
down and to the right, without total recovery of the
maximal response (;60% of the maximal response to
AII is achieved). This insurmountable activity of irbe-
sartan is evident independent of AII concentrations
and does not require conversion to an active metabo-
lite.
Studies in Healthy Subjects Two randomized, dou-
ble blind, placebo controlled, parallel studies involv-
ing a total of 42 healthy subjects assessed the ability of
irbesartan to inhibit the pressor response to exogenous
AII.20,21 Irbesartan was administered at single, oral
doses ranging from 25 to 300 mg. Irbesartan 150 and
300 mg inhibited the pressor response elicited by AII
up to 100% at peak (2 to 4 h postdose), with 45% to
60% inhibition still present 24 h after dosing, respec-
tively (Figure 6). Plasma concentrations of irbesartan
were proportional to dose and paralleled the inhibi-
tion of the AII-induced pressor response. As presented
in Figure 7, losartan 40 mg inhibited the same re-
sponse by a maximum of 70%,22,23 whereas higher
doses (80 and 120 mg)24 caused near maximal inhibi-
tion (94%). The extent of inhibition with losartan was
the same at 24 h (;45%), regardless of dose.22–24
Studies in Hypertensive Patients The interesting
question is whether this model of exogenous AII chal-
lenge in healthy subjects reflects the efficacy observed
in hypertensive patients. The results of seven random-
ized, placebo controlled studies demonstrate clinically
significant reductions in blood pressure with irbesar-
tan and a clear relationship between dose (up to 300
mg) and antihypertensive response (see Dr. Hubert
Pouleur’s ‘‘Clinical Overview of Irbesartan: A New
Angiotensin II Receptor Antagonist’’25 in this supple-
ment). Thus, a 300 mg dose of irbesartan provides
maximal blockade of the AII pressor response in
healthy subjects and appears to represent the upper
end of the clinical dose range.
The first large scale, multicenter study with losartan
included patients with an average baseline blood pres-
sure of 157/104 mm Hg.26,27 Patients were randomly
allocated to either double-blind losartan (10, 25, 50,
100, or 150 mg), 20 mg enalapril, or placebo once daily
for 8 weeks. At week 8, neither the 10 mg nor the 25
mg doses of losartan caused statistically significant
decreases in diastolic blood pressure at trough,
whereas higher doses all statistically significantly re-
duced trough diastolic blood pressure compared with
FIGURE 6. Time profile of the mean response to exogenous
angiotensin II challenge after single oral doses of irbesartan in
healthy subjects (n 5 6/group).
FIGURE 7. Time profile of the mean response to exogenous
angiotensin II challenge after single oral doses of losartan in
healthy subjects (n 5 6/group); adapted from Munafo et al.24
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placebo. However, reductions in trough diastolic
blood pressure associated with losartan 50 mg were at
least equal to those produced with higher losartan
doses, suggesting that a 50 mg dose may represent the
upper end of the dose-response curve for losartan. The
50 mg dose of losartan is situated between the 40 and
80 mg doses that were predicted as the range for
maximum AII blockade. The competition at the recep-
tor site between losartan, a competitive antagonist,
and its metabolite, a noncompetitive antagonist (both
with different kinetics and affinity), might explain the
lack of apparent dose related efficacy for this drug.
CONCLUSIONS
Angiotensin II blockers are an important addition to
the treatment options for hypertension. Within this
drug class, there exist some clear differences in phar-
macokinetics (eg, oral bioavailability, food interaction,
duration of effect, protein binding, and active metab-
olites). Irbesartan, a novel AIIRA, has an excellent
pharmacokinetic profile that seems to provide some
advantages to those of other agents in its class. The
pharmacokinetic and pharmacodynamic differences
highlighted in this article may have clinical relevance.
Potential differences in clinical effectiveness are cur-
rently being studied in blinded, randomized clinical
trials.
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